What does the death of Riquent™ hold for the future of SLE?

Nature Reviews Rheumatology

Volumn 5, Issue 6, 2009, Pages 306-307

  Merrill, Joan T ^a   Buyon, Jill P ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; OLIGONUCLEOTIDE;

HUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OLIGONUCLEOTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 68849120941     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.99     Document Type: Short Survey

References (10)

1. Dey, E. UPDATE 2-La Jolla stops developing lupus drug; shares tank. www.reuters.com/article/marketsnews/idUsBnG16819820090212 (2009).
2. Study of LJP 394 in lupus patients with history of renal disease (AsPen). www.clinicaltrials.gov/ct2/show/nCT00089804 (2009).
3. Furie, R. A. et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28, 257-265 (2001).
4. Alarcón-segovia, D. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48, 442-454 (2003).
5. Cardiel, M. H. et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase iii trial. Arthritis Rheum. 58, 2470-2480 (2008).
6. Alarcón, G. S. et al. Baseline characteristics of a multiethnic lupus cohort: PROFiLe. Lupus 11, 95-101 (2002).
7. Dooley, M. A. & Ginzler, E. M. newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum. Dis. Clin. North Am. 32, 91-102 (2006).
8. Linnik, M. D., O'Rourke, A. M. & Crowther, M. A. Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. J. Clin. Pharmacol. 48, 909-918 (2008).
9. Buyon, J. P. neonatal lupus syndromes. Am. J. Reprod. Immunol. 28, 259-263 (1992).
10. López, P., Gómez, J., Prado, C., Gutiérrez, C. & suárez, A. influence of functional interleukin 10/tumor necrosis factor-α polymorphisms on interferon-α, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J. Rheumatol. 35, 1559-1566 (2008).